PL BioScience GmbH
PL BioScience GmbH specializes in the production of Human Platelet Lysate (HPL) and the development of next generation cell culture media.
HPL is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. Natural HPL is produced from human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a more sustainable and safer alternative to animal-derived cell culture supplements.
The Company has pioneered proprietary technology to produce artificial HPL for a fully lab-made, scalable supply of HPL to support innovative drug development. A newly announced 1,200 m² headquarters will support growth and scale-up efforts, producing 20,000 L of HPL annually to ensure secure, resilient supply from Aachen.
PL BioScience GmbH
| Field of Activity | PL BioScience creates advanced cell culture supplements for innovative cell-based therapies. It supports cell therapy research, regenerative medicine, and biopharmaceutical manufacturing with its xeno-free Human Platelet Lysate (HPL) ELAREMTM platform. A fully artificial HPL, which combines the advantages of natural HPL with the scalability of lab-made supplements, is in development to meet the growing global demand for safe, animal-free cell culture supplements. |
| Ownership Structure and Financing | International VCs and Business Angels / Family Offices. |
| Partners | DewCell (Korea): collaboration on supply of artificial platelet raw material to support next-generation HPL production. |
| Products/ Services | PL BioScience offers a comprehensive portfolio of donor- derived, natural HPL products tailored for a range of applications. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, the ELAREMTM platform ensures seamless translations of regenerative medicine breakthroughs from the lab to patients in need. The ELAREM™ platform is a portfolio of cell culture media based on human platelets. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS. |
| Unique Selling Point | The only company in Europe harnessing the broad potential of human platelets and scaling up to power innovative cell therapies and regenerative medicine breakthroughs. |
Kontakt:
| Address | Auf der Hüls 184- 186 52068 Aachen, Germany |
| Telephone | +49 241 95719-100 |
| info@pl-bioscience.com | |
| Web Address | PL BioScience » Broadest portfolio of Human Platelet Lysate |
| Date of Incorporation/ Number of Employees | 2015/21 |